Hepion Pharmaceuticals Inc (HEPA)

[TradeSmart.ai]

Maxim Group set a $4.00 price target on shares of ContraVir Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, April 11th. Noble Financial reaffirmed a “Buy” rating on shares of ContraVir Pharmaceuticals in a research report on Friday, April 21st.

Teachers Advisors LLC boosted its position in ContraVir Pharmaceuticals by 3.1% in the fourth quarter. Teachers Advisors LLC now owns 298,781 shares of the biopharmaceutical company’s stock worth $1,820,000 after buying an additional 8,862 shares during the last quarter. Vanguard Group Inc. boosted its position in ContraVir Pharmaceuticals by 10.2% in the first quarter. Vanguard Group Inc. now owns 2,048,283 shares of the biopharmaceutical company’s stock worth $3,626,000 after buying an additional 189,634 shares during the last quarter. Geode Capital Management LLC boosted its position in ContraVir Pharmaceuticals by 2.0% in the first quarter. Geode Capital Management LLC now owns 353,777 shares of the biopharmaceutical company’s stock worth $626,000 after buying an additional 7,057 shares during the last quarter. Finally, Morgan Stanley boosted its position in ContraVir Pharmaceuticals by 0.4% in the first quarter. Morgan Stanley now owns 278,798 shares of the biopharmaceutical company’s stock worth $493,000 after buying an additional 1,119 shares during the last quarter. 5.49% of the stock is owned by institutional investors.


Very nice averages stakes taken by numerous groups and this is a month or two before the conferences. Shows some agencies might have gotten a sneak peak at the upcoming info. $CTRV